

## New results on Essilor Stellest™ lens to be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO 2021)

- Pivotal two-year clinical trial results demonstrate that Essilor Stellest™ lens slows down myopia progression by 67%<sup>1</sup>
- These results focusing on Essilor Stellest™ lens will be presented for the first time internationally at the occasion of the 2021 Annual Meeting of the ARVO

(Charenton-le-Pont, 9 April, 2021) – Essilor will unveil the pivotal two-year clinical trial results of its Stellest™ lens - its latest breakthrough spectacle lens solution in the fight against myopia. The much-anticipated two-year results demonstrate that Essilor Stellest™ lenses slow down myopia progression by 67% on average, when compared to single vision lenses, when worn at least 12 hours a day<sup>1</sup>.

The presentation of this research entitled “*Myopia control with spectacle lenses with aspherical lenslets: a 2-year randomized clinical trial*”, will be delivered at the occasion of the Annual Meeting of the ARVO, on May 6<sup>th</sup>, 2021, by BAO Jinhua<sup>2</sup>, Associate Professor at Wenzhou Medical University, China.

In 2018, Essilor’s research and development team initiated a three-year state-of-the-art clinical trial on 167 myopic children<sup>3</sup> in its joint Research and Development Center shared with key partner, the Wenzhou Medical University, in China. This research illustrates Essilor’s commitment to fight poor vision and to find concrete solutions to slow down myopia progression in childhood.

The results of this study demonstrate compelling evidence that Essilor Stellest™ lenses are one of the most effective options available for slowing down myopia progression in children today. Key outcomes include:

- After two years, children wearing Essilor Stellest™ lenses saved 0.99 diopters of myopia degree on average (67% slow-down in myopia progression on average), compared to single vision lenses, when worn 12 hours or more per day every day.
- After the first year, the eye growth of 9 out of 10 children wearing Essilor Stellest™ lenses was similar or slower than non-myopic children<sup>1</sup>.
- 2 out of 3 children who wore Essilor Stellest™ lenses did not need a prescription change after the first year<sup>1</sup>.
- 100% of children wearing Essilor Stellest™ lenses had clear vision, 100% of children adapted to their new lenses within a week; 91% of children fully adapted within three days; and 94% of children felt comfortable with Essilor Stellest™ lenses, demonstrating that Essilor Stellest™ lenses were comfortable, and easy to adapt for children<sup>1</sup>.

**Norbert Gorny, Co-Chief Operating Officer, Essilor International commented on the results, “With such impressive results, Essilor’s Stellest™ lenses will truly be a catalyst to stem myopia progression and to help children, who continue to be at risk of sight-threatening eye conditions associated with myopia. Essilor is proud to be at the forefront of myopia management and we will continue to be focused on bringing such innovative advances to move the needle on the fight against myopia.”**

**Grita Loeb sack, Group Chief Marketing Officer, Essilor International said,** *“These exciting results have already amazed leading global myopia experts and illustrate that Essilor’s mission and commitment to tackle myopia remains stronger than ever today. Essilor’s Stellest™ lenses are one of the most effective myopia control spectacle lenses in the world and a true breakthrough in the optical industry. After its successful release in China in June 2020, then in Russia and Singapore, with extremely positive feedback from parents, children and eye care practitioners, we look forward to offering this new solution to help children in other countries.”*

The Essilor Stellest™ lenses provide myopia correction through a single vision lens, which allows for sharp far vision and myopia control through H.A.L.T.<sup>4</sup> technology, which consists of a constellation of aspherical lenslets spread on 11 rings and was designed to create for the first time, a volume of signal that slows down the elongation of the eye. The power of lenslets on each ring has been determined to guarantee a volume of signal always in front of the retina and following its shape, to achieve consistent myopia slowdown

In addition to innovation and research, Essilor is committed to strengthening awareness and education of myopia with governments, healthcare and eye care professionals, and the wider public. Essilor pledged its support for the publication of International Myopia Institute’s landmark white papers in 2019, and is also a member of the industry-wide Global Myopia Awareness Coalition to raise awareness of myopia. Essilor has also recently partnered with leading international myopia educational company, Myopia Profile, to jointly empower eye care practitioners with clinical knowledge, skills and practice in managing childhood myopia.

---

<sup>1</sup> Compared to single vision lenses, when worn at least 12 hours a day. Two-year prospective, controlled, randomized, double-masked clinical trial results - 104 myopic children split in two groups: Single vision lenses (50) and Essilor Stellest™ lenses (54) - Efficacy results are based on 32 children who declared wearing Essilor Stellest™ lenses at least 12 hours per day every day - Eye Hospital of the Wenzhou Medical University - J. Bao, A. Yang, Y. Huang, X. Li, Y. Pan, C. Ding, E. W. Lim, J. Zheng, D. P. Spiegel, Y. L. Wong, B. Drobe, F. Lu, H. Chen

<sup>2</sup> Associate Professor and Co-PI, Lab of Myopia and Visual Performance, Eye Hospital of Wenzhou Medical University and Associate Director of Wenzhou Medical University - Essilor International Research Center (WEIRC)

<sup>3</sup> The children in the study were between 8 and 13 years old and were divided into a treatment group equipped with Essilor Stellest™ lenses and a control group with single vision lenses.

<sup>4</sup> Highly Aspherical Lenslet Target

#### About Essilor

*Essilor International is the world’s leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, Eyezen™, Xperio®, Foster Grant®, and Bolon™. It also develops and markets equipment, instruments and services for eyecare professionals. Essilor International is a subsidiary of EssilorLuxottica. For more information, please visit [www.essilor.com](http://www.essilor.com)*

## CONTACTS

### Corporate Communications

Ginette De Matteis

Tel.: +33 (0)1 49 77 45 02

### Media Relations

Mailis Thiercelin

Tel.: +33 (0)1 49 77 45 02